Thermo Fisher Buys Solventum's Purification and Filtration Business for $4.1 Billion
Thermo Fisher Scientific is acquiring Solventum's purification and filtration business for $4.1 billion, a deal expected to expand the company's presence in bioprocessing. The acquisition should allow Thermo to gain entry into the filtration category, where peers Danaher and Repligen are more strongly positioned. Thermo expects the deal to be dilutive in its first year of ownership but accretive by 2025.
- This strategic move highlights the importance of access to specialized technologies and expertise in driving growth and competitiveness within the pharmaceutical industry.
- How will Thermo Fisher's acquisition strategy influence the broader bioprocessing market, potentially shifting the balance of power among key players?